Formycon Wins Endorsement For Second EU Lucentis Rival
CHMP Positive Opinion For Ranivisio Sets Up Approval For Ranibizumab Biosimilar
Formycon has seen its FYB201 ranibizumab biosimilar rival to Lucentis recommended for approval by the EMA’s CHMP, under the name Ranivisio. Teva has rights to market the product in Europe and is preparing for launch.
